CY1125201T1 - Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma) - Google Patents

Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma)

Info

Publication number
CY1125201T1
CY1125201T1 CY20221100255T CY221100255T CY1125201T1 CY 1125201 T1 CY1125201 T1 CY 1125201T1 CY 20221100255 T CY20221100255 T CY 20221100255T CY 221100255 T CY221100255 T CY 221100255T CY 1125201 T1 CY1125201 T1 CY 1125201T1
Authority
CY
Cyprus
Prior art keywords
prodrugs
psma
prostate
inhibitor
specific membrane
Prior art date
Application number
CY20221100255T
Other languages
English (en)
Inventor
Barbara Slusher
Rana RAIS
Marcela Krecmerova
Tomas Tichy
Pavel Majer
Andrej JANCARIK
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of CY1125201T1 publication Critical patent/CY1125201T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4084—Esters with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4087—Esters with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4465—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Αποκαλύπτονται μέθοδοι και ενώσεις για τη θεραπεία μιας νόσου ή κατάστασης δια αναστολής του PSMA (Προστατικό Ειδικό Αντιγόνο Μεμβράνης) με τη χρήση προφαρμάκων του 2-ΡΜΡΑ.
CY20221100255T 2014-08-06 2022-04-04 Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma) CY1125201T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033926P 2014-08-06 2014-08-06
PCT/US2015/044053 WO2016022827A1 (en) 2014-08-06 2015-08-06 Prodrugs of prostate specific membrane antigen (psma) inhibitor

Publications (1)

Publication Number Publication Date
CY1125201T1 true CY1125201T1 (el) 2024-02-16

Family

ID=55264571

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100255T CY1125201T1 (el) 2014-08-06 2022-04-04 Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma)

Country Status (14)

Country Link
US (4) US9988407B2 (el)
EP (1) EP3177632B1 (el)
CA (1) CA2961880C (el)
CY (1) CY1125201T1 (el)
DK (1) DK3177632T3 (el)
ES (1) ES2908411T3 (el)
HR (1) HRP20220446T1 (el)
HU (1) HUE058072T2 (el)
LT (1) LT3177632T (el)
PL (1) PL3177632T3 (el)
PT (1) PT3177632T (el)
RS (1) RS63082B1 (el)
SI (1) SI3177632T1 (el)
WO (1) WO2016022827A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3495355A1 (en) 2013-10-18 2019-06-12 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA2961575C (en) * 2014-08-06 2023-09-19 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
HRP20220446T1 (hr) 2014-08-06 2022-05-27 The Johns Hopkins University Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma)
JP2020530007A (ja) * 2017-04-11 2020-10-15 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｓｍａ標的化ガンイメージングまたは放射線療法中の健康組織保護のための２−ｐｍｐａのプロドラッグ
GB201810965D0 (en) * 2018-07-04 2018-08-15 Univ College Cardiff Consultants Ltd Phosphoantigen prodrug compounds
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
US20210323985A1 (en) * 2018-09-21 2021-10-21 Endocyte, Inc. Shielding agents and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
ATE489103T1 (de) 2001-10-26 2010-12-15 Scripps Research Inst Gezielte thrombose durch gewebefaktor polypeptiden
US20060046978A1 (en) 2004-08-31 2006-03-02 Morphochem Ag Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
CA2961575C (en) * 2014-08-06 2023-09-19 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
HRP20220446T1 (hr) * 2014-08-06 2022-05-27 The Johns Hopkins University Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma)

Also Published As

Publication number Publication date
US20170226141A1 (en) 2017-08-10
CA2961880C (en) 2022-09-27
US20180244705A1 (en) 2018-08-30
HUE058072T2 (hu) 2022-07-28
PT3177632T (pt) 2022-03-21
LT3177632T (lt) 2022-04-25
WO2016022827A1 (en) 2016-02-11
HRP20220446T1 (hr) 2022-05-27
US11932664B2 (en) 2024-03-19
EP3177632A1 (en) 2017-06-14
US11325931B2 (en) 2022-05-10
CA2961880A1 (en) 2016-02-11
EP3177632B1 (en) 2022-01-12
RS63082B1 (sr) 2022-04-29
US20230115651A1 (en) 2023-04-13
DK3177632T3 (da) 2022-03-21
ES2908411T3 (es) 2022-04-29
EP3177632A4 (en) 2018-04-04
US10544176B2 (en) 2020-01-28
US9988407B2 (en) 2018-06-05
US20200399298A1 (en) 2020-12-24
PL3177632T3 (pl) 2022-06-13
SI3177632T1 (sl) 2022-05-31

Similar Documents

Publication Publication Date Title
CY1125201T1 (el) Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma)
CY1120988T1 (el) Παρεμποδιστες διαρυλ κινασης
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201891211A1 (ru) Ингибиторы cxcr2
CO2017004314A2 (es) Compuestos anti-tnf
DK3469425T3 (da) Strålingskilde
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
CY1121602T1 (el) Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
EA201991818A1 (ru) Лечение рака
EA201790019A1 (ru) Способ выбора персонализированной трехкомпонентной терапии для лечения рака
IT201700048561A1 (it) Lampada per serre
CY1120131T1 (el) Επαφεας για μια στηλη ανταλλαγης που αποτελειται απο μια διαταξη δομικων επενδυσεων
DK3688530T3 (da) Strålingskilde
ITUA20162315A1 (it) Calzatura post-operatoria
BR112017002139A2 (pt) ?método para preparar um composto?
FR3031502B1 (fr) Ensemble de pointage d'un instrument
MX2016015298A (es) Inhibidores de nampt y metodos.
DK3573713T3 (da) Fodtøj til magnetterapi
DK3326685T3 (da) Cochleaimplantatsystem til behandling af multipel lydkildeinformation
DK3459083T3 (da) Fremgangsmåde til at tilvejebringe en neutronkilde
SE1530091A1 (el)